September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Navigated retinal photocoagulation (NaviLas®) as an alternative therapy in patients with refractory central serous chorioretinopathy
Author Affiliations & Notes
  • Jan Klonner
    Department of Ophthalmology, Charité - Medical University Berlin Campus Virchow, Berlin, Germany
  • Juliane Schlomberg
    Department of Ophthalmology, Charité - Medical University Berlin Campus Virchow, Berlin, Germany
  • Anne Rübsam
    Department of Ophthalmology, Charité - Medical University Berlin Campus Virchow, Berlin, Germany
  • Tina Dietrich-Ntoukas
    Department of Ophthalmology, Charité - Medical University Berlin Campus Virchow, Berlin, Germany
  • Sibylle Winterhalter
    Department of Ophthalmology, Charité - Medical University Berlin Campus Virchow, Berlin, Germany
  • Antonia Joussen
    Department of Ophthalmology, Charité - Medical University Berlin Campus Virchow, Berlin, Germany
  • Bert Müller
    Department of Ophthalmology, Charité - Medical University Berlin Campus Virchow, Berlin, Germany
  • Footnotes
    Commercial Relationships   Jan Klonner, None; Juliane Schlomberg, None; Anne Rübsam, None; Tina Dietrich-Ntoukas, None; Sibylle Winterhalter, None; Antonia Joussen, None; Bert Müller, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5359. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jan Klonner, Juliane Schlomberg, Anne Rübsam, Tina Dietrich-Ntoukas, Sibylle Winterhalter, Antonia Joussen, Bert Müller; Navigated retinal photocoagulation (NaviLas®) as an alternative therapy in patients with refractory central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5359.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There are different therapeutic strategies in the treatment of central serous chorioretinopathy (CSC). Laser coagulation of source points visible in the fluorescein angiography is a possibility, usually in patients with chronic CSC (more than 6 months) without improvement, spontaneous, or under treatment with acetazolamide or spironolactone. Due to the risk of photoreceptor damage and possible central scotoma, conventional laser treatmeant is usually not recommended close to the foveal avascular zone. We hypothesize that NaviLas® (OD-OS, Teltow, Germany) offers a safe way of navigated and assisted, FAG image based, lasercoagulation of juxta- and parafoveal source points.

Methods : Retrospective analysis of 10 eyes from 10 subjects (mean age 43.4 ± 8.2 years) with chronic refractory CSC, which were treated between 2013-2015 in our clinic with NaviLas® at source points in the macular area, 6 of them juxtafoveal. We analyzed the best-corrected visual acuity (BCVA) before and one month after treatment, as well as the average central retinal thickness (meanCRT) in SD-OCT (Heidelberg Engineering©, Heidelberg, Germany).

Results : Before laser treatment 3 of 10 patients recieved a treatment trial of acetazolamide and spironolactone, 2 patients spironolactone only and 5 patients acetazolamide only. In all of the patients treatet with NaviLas®, with 3 to 5 laserspots per source point, we found a significant improvement in visual acuity from 0.28 ± 0.19 LogMAR to 0.16 ± 0.22 (p = 0.01 at α <0.05) and a significant reduction in mean CRT from 439, 4 ± 116.1 to 273.6 ± 69,1 (p = 0.005 at α <0.05). No patient experienced a treatment-induced visual loss.

Conclusions : Laser treatment with NaviLas® using eye tracking and FA based planning options seems to be a safe and effective alternative therapy in patients with chronic refractory CSC. In the current follow-up period, all patients were stabilized and displayed a lack of recurrence of original symptoms. We found a total resorption of subretinal fluid in 7 of 10 subjects. However, further studies with larger numbers of patients and longer follow-up times are planned to investigate long term effects.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×